Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Lignende værker

• Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
  af: Yoon, Hee-Young, et al.
  Udgivet: (2020)
• Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
  af: Yang, Hua, et al.
  Udgivet: (2016)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  af: Wu, Shang-Gin, et al.
  Udgivet: (2020)
• Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
  af: Chang, Yoon Soo, et al.
  Udgivet: (2016)
• Epidermal growth factor receptor tyrosine kinase inhibitors
  af: Ranson, M
  Udgivet: (2004)